Poxel

Poxel is a company headquartered in France. Brouky classifies it under Healthcare & Life Sciences.

Poxel is a clinical-stage biopharmaceutical company developing drug candidates targeting metabolic diseases, including treatments for type 2 diabetes, non-alcoholic steatohepatitis (NASH), and rare metabolic disorders. Its pipeline includes marketed drug TWYMEEG® (Imeglimin) in Japan and mid-stage candidates PXL065 and PXL770 focusing on NASH and rare diseases.